Factors determining pubertal growth and final height in growth hormone treatment of idiopathic growth hormone deficiency. Analysis of 195 Patients of the Kabi Pharmacia International Growth Study
- PMID: 9251922
- DOI: 10.1159/000185487
Factors determining pubertal growth and final height in growth hormone treatment of idiopathic growth hormone deficiency. Analysis of 195 Patients of the Kabi Pharmacia International Growth Study
Abstract
A total of 195 children (117 males and 78 females) with idiopathic growth hormone deficiency (IGHD) treated with growth hormone (GH) for at least 1 year before puberty onset and who had completed treatment to adult height, were selected from the KIGS database for study of growth during puberty. Spontaneous and induced puberty started at 13.8 and 14.9 years in boys and at 12.9 and 13.7 years in girls, respectively. Duration of GH treatment and height gained prepubertally were greater when puberty was induced; prepubertal catch up growth (expressed as a percentage of the difference between target height and height at start of GH) was greater when puberty was induced in boys (59% induced vs. 45% spontaneous, p < 0.001), and in girls (72% induced vs. 53.9% spontaneous, p < 0.01). Final height was attained at 17.8 and 19.2 years in boys and at 16.0 and 17.0 years in girls following spontaneous and induced puberty, respectively. Final heights were greater after induced puberty compared with spontaneous puberty in boys (171.3 vs. 166.0 cm, p < 0.001) and in girls (157.0 vs. 155.0 cm, n.s.). Target height was also significantly greater in boys with spontaneous puberty (172.2 cm vs. induced = 174.2 cm) as compared to girls (spontaneous = 158 cm vs. induced = 160 cm). Duration of pubertal growth was longer in boys compared to girls (3.6 vs. 3.0 years, p < 0.001) and was negatively correlated with age, height, and distance from target height at onset of puberty, but was not correlated with the dose of GH. Catch-up growth during puberty (expressed as a percentage of the difference between target height and height at puberty onset) after induced and spontaneous puberty was 87.9% and 80.5% (not significant) in boys and 66.4% and 75.5% (not significant in girls. Total pubertal growth (TPG) (cm) was inversely correlated with prepubertal growth by simple linear regression. Multiple linear regression analysis indicated 5 independent predictors of TPG accounting for 78% of the variability, namely sex (boys grew more), distance of target height from height at onset of puberty (+), dose of GH at onset of puberty (+), age at onset of puberty (-), and age at end of growth (+).
Similar articles
-
Puberty and Pubertal Growth in GH-treated SGA Children: Effects of 2 Years of GnRHa Versus No GnRHa.J Clin Endocrinol Metab. 2016 May;101(5):2005-12. doi: 10.1210/jc.2016-1317. Epub 2016 Mar 10. J Clin Endocrinol Metab. 2016. PMID: 26964733
-
Growth response, pubertal growth and final height in Greek children with growth hormone (GH) deficiency on long-term GH therapy and factors affecting outcome.J Pediatr Endocrinol Metab. 2001 Apr;14(4):397-405. doi: 10.1515/jpem.2001.14.4.397. J Pediatr Endocrinol Metab. 2001. PMID: 11327373
-
Observed and predicted total pubertal growth during treatment with growth hormone in adolescents with idiopathic growth hormone deficiency, Turner syndrome, short stature, born small for gestational age and idiopathic short stature: KIGS analysis and review.Horm Res Paediatr. 2011;75(6):423-32. doi: 10.1159/000324117. Epub 2011 Feb 25. Horm Res Paediatr. 2011. PMID: 21358173 Review.
-
When and how to combine growth hormone with a luteinizing hormone-releasing hormone analogue.Acta Paediatr Suppl. 1999 Feb;88(428):85-8. doi: 10.1111/j.1651-2227.1999.tb14359.x. Acta Paediatr Suppl. 1999. PMID: 10102060 Clinical Trial.
-
Effects of growth hormone therapy on the onset and progression of pubertal development in girls with idiopathic short stature.Gynecol Endocrinol. 2024 Dec;40(1):2358227. doi: 10.1080/09513590.2024.2358227. Epub 2024 May 28. Gynecol Endocrinol. 2024. PMID: 38807420 Review.
Cited by
-
The use of somatropin (recombinant growth hormone) in children of short stature.Paediatr Drugs. 2002;4(1):37-47. doi: 10.2165/00128072-200204010-00005. Paediatr Drugs. 2002. PMID: 11817985 Review.
-
Growth hormone therapy in childhood-onset growth hormone deficiency: adult anthropometric and psychological outcomes.Endocrine. 2000 Apr;12(2):173-82. doi: 10.1385/endo:12:2:173. Endocrine. 2000. PMID: 10905377 Review.
-
Early detection of growth disorders with the CrescNet system at the Leipzig treatment center.Dtsch Arztebl Int. 2011 Feb;108(8):123-8. doi: 10.3238/arztebl.2011.0123. Epub 2011 Feb 25. Dtsch Arztebl Int. 2011. PMID: 21403802 Free PMC article.
-
The first-year growth response to growth hormone treatment predicts the long-term prepubertal growth response in children.BMC Med Inform Decis Mak. 2009 Jan 12;9:1. doi: 10.1186/1472-6947-9-1. BMC Med Inform Decis Mak. 2009. PMID: 19138407 Free PMC article.
-
Monitoring Adherence Rate to Growth Hormone Therapy and Growth Outcomes in Taiwanese Children Using Easypod Connect: Observational Study.JMIR Pediatr Parent. 2021 Jan 15;4(1):e14774. doi: 10.2196/14774. JMIR Pediatr Parent. 2021. PMID: 33448936 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous